Sarah M Abu Fadaleh
Overview
Explore the profile of Sarah M Abu Fadaleh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karimi-Shahrbabak E, Di Chiara C, Farrar D, Abu Fadaleh S, Peresin J, Low B, et al.
Vaccine
. 2024 May;
42(19):3974-3980.
PMID: 38772834
Introduction: Although COVID-19 vaccine safety in 5-11-year-old children has been documented, half of Ontarian children this age remain unvaccinated. This study aimed to assess caregivers' vaccine acceptance for 5-11-year-old children...
2.
Farrar D, Pell L, Muhammad Y, Khan S, Tanner Z, Bassani D, et al.
PLOS Glob Public Health
. 2024 Feb;
4(2):e0002693.
PMID: 38412169
Pakistan has among the highest rates of maternal, perinatal, and neonatal mortality globally. Many of these deaths are potentially preventable with low-cost, scalable interventions delivered through community-based health worker programs...
3.
Abu Fadaleh S, Pell L, Yasin M, Farrar D, Khan S, Tanner Z, et al.
BMC Public Health
. 2023 Dec;
23(1):2480.
PMID: 38082395
Background: Ongoing high neonatal mortality rates (NMRs) represent a global challenge. In 2021, of the 5 million deaths reported worldwide for children under five years of age, 47% were newborns....
4.
Abu Fadaleh S, Shkrobot J, Makhinova T, Eurich D, Sadowski C
Res Social Adm Pharm
. 2020 Apr;
16(12):1792-1797.
PMID: 32249103
Objective: Deprescribing has several barriers, including financial implications; the purpose of this study is to determine the financial impact of deprescribing on the pharmacy, public payer (government), and the patient,...